AR100237A1 -
LAQUINIMOD FOR THE TREATMENT OF PATIENTS WITH MULTIPLE RECURRENT MULTIPLE SCLEROSIS (RRMS) WITH A HIGH DEGREE OF DISABILITY
- Google Patents
LAQUINIMOD FOR THE TREATMENT OF PATIENTS WITH MULTIPLE RECURRENT MULTIPLE SCLEROSIS (RRMS) WITH A HIGH DEGREE OF DISABILITY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva PharmafiledCriticalTeva Pharma
Publication of AR100237A1publicationCriticalpatent/AR100237A1/en
Un método para tratar o para reducir el deterioro ambulatorio en un paciente humano con un diagnóstico de esclerosis múltiple remitente recurrente (RRMS) y que tiene una puntuación elevada de discapacidad basal de acuerdo a la Escala Ampliada de Estado de Discapacidad de Kurtzke (EDSS), que comprende administrar periódicamente solamente al paciente con diagnóstico de RRMS y que tiene una puntuación de discapacidad basal alta, una cantidad de laquinimod eficaz para tratar al paciente o para reducir el deterioro ambulatorio. Además provee composiciones farmacéuticas y paquetes que comprenden una cantidad eficaz de laquinimod para tratar un paciente humano con un diagnóstico de RRMS y que tiene una puntuación elevada de discapacidad basal de acuerdo a la EDSS.A method of treating or reducing ambulatory impairment in a human patient with a diagnosis of recurrent remitting multiple sclerosis (RRMS) and who has a high baseline disability score according to the Kurtzke Expanded Status of Disability Scale (EDSS), which comprises periodically administering only to the patient with a diagnosis of RRMS and who has a high baseline disability score, an amount of effective laquinimod to treat the patient or to reduce ambulatory impairment. It also provides pharmaceutical compositions and packages that comprise an effective amount of laquinimod to treat a human patient with a diagnosis of RRMS and that has a high baseline disability score according to the EDSS.
ARP150101303A2014-04-292015-04-29
LAQUINIMOD FOR THE TREATMENT OF PATIENTS WITH MULTIPLE RECURRENT MULTIPLE SCLEROSIS (RRMS) WITH A HIGH DEGREE OF DISABILITY
AR100237A1
(en)
USE OF LAQUINIMOD FOR THE TREATMENT OF PATIENTS WITH CROHN'S DISEASE IN THOSE WHO FAILS AN ANTI-FACTOR THUMOR NECROSIS THERAPY a (ANTI-TNFa) FIRST LINE
Use of methotrexate because it is used to prepare a medicine, useful in the treatment of diseases that need treatment with a therapeutic product that produces autoimmunity, administered in a single cycle.